Nuvectis Pharma, Inc.
NASDAQ:NVCTBiotechnology
+$0.39 today
- Market cap
- $697.75M
- Beta
- -0.07
- P/E (TTM)
- -11.2
- EPS (TTM)
- -$1.16
Volume 0.19M
Average 0.08M
NVCT Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Nuvectis Pharma, Inc.NASDAQ: NVCT
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 15.9% from a year ago
Cash & equivalents stood at $25.13M at the end of Q1 FY2026, down 15.9% from a year earlier and down 20.6% from the prior quarter. Over 3 fiscal years it compounded at +16.5% a year.
Context
- Cash & equivalents amounted to 98.9% of total assets at the end of Q1 FY2026, down 0.1 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -15.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 31.63M USD
- Year-over-year change
- +70.7%
- 4-year CAGR
- +53.2%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 31.63M | +70.7% |
| FY2024 | 2024-12-31 | 18.53M | -3.1% |
| FY2023 | 2023-12-31 | 19.13M | -4.3% |
| FY2022 | 2022-12-31 | 19.99M | +248.2% |
| FY2021 | 2021-12-31 | 5.74M | — |
Cash & Equivalents vs competitors
How NVCT compares with its peers on the latest reported figures
- NVCT's Mar 2026 cash & equivalents of $25.13M is the lowest of the 11 companies compared; the peer median is $61.46M.
- Its year-over-year change of -15.9% is the 8th highest of 11, against a peer median of +9.3%.
- Cash & equivalents amounts to 98.9% of total assets for NVCT, versus a peer median of 29.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $258.6M | +4.3% | +17.5% | 34.7% | |
| Mar 2026 | $165.55M | +40.8% | +39.9% | 72.7% | |
| Mar 2026 | $130.89M | -15.0% | +22.0% | 27.7% | |
| Mar 2026 | $79.25M | +397.8% | +91.2% | 82.7% | |
| Mar 2026 | $66.52M | -54.3% | -19.3% | 30.5% | |
| Mar 2026 | $56.4M | +14.3% | -11.9% | 12.9% | |
| Mar 2026 | $55.17M | +34.4% | -4.3% | 26.9% | |
| Mar 2026 | $51.83M | -29.7% | +0.6% | 5.0% | |
| Mar 2026 | $47.32M | +31.9% | +21.0% | 0.0% | |
| Mar 2026 | $36.22M | -42.0% | -15.6% | 89.2% | |
| Mar 2026 | $25.13M | -15.9% | +16.5% | 98.9% | |
| Peer median (excluding NVCT) | $61.46M | +9.3% | +9.1% | 29.1% | |
Competitors are the stored peer set for NVCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Nuvectis Pharma, Inc.
NASDAQ:NVCT
Intrinsic Alpha fair value
Locked
Current Price
$20.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.